Follicular Lymphoma Secondary to Chronic Myeloid Leukemia During Treatment With Imatinib

Tyrosine kinase inhibitors (TKIs) remain the mainstay of treatment for those with chronic myeloid leukemia (CML); nonetheless, there is concern over the possibility of additional cancers as a result of TKI use. There are not many cases in the literature where tyrosine kinase treatment caused a patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Geelani, Sajad A, Rathod, Santosh G, Dhar, Amrit, Atri, Pallavi, Bhat, Javid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790149/
https://www.ncbi.nlm.nih.gov/pubmed/36579283
http://dx.doi.org/10.7759/cureus.31884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9790149/
https://www.ncbi.nlm.nih.gov/pubmed/36579283
http://dx.doi.org/10.7759/cureus.31884

Ejemplares similares